Myopia and Presbyopia Treatment Market Size & Share, by Treatment Type (Surgical Procedures, Pharmacological Agents, Corrective Lenses, Contact Lenses, Implantable Devices, Combination Therapies); Drug Type, End user - SWOT Analysis, Competitive Strategic Insights, Regional Trends 2025-2037

Myopia and Presbyopia Treatment Market - Regional Analysis

North America Market Insights 

North America is the dominant region in the myopia and presbyopia treatment market and is expected to hold the market share of 38.1% at a CAGR of 7.2% by 2037. The market is driven by the favorable reimbursement policies, innovation in pharmacological therapies, and high procedure volumes. The U.S. market is the revenue anchor and is mainly driven by the Medicare and Medicaid expansions. The need for therapy is increasing increased to the rising incidence of visual diseases, which are connected to aging populations and digital screen exposure. Industry-wide, med-tech companies and pharmaceutical companies are actively using AI-based diagnostics and personalized vision correction tools with government support for innovation goals.

The myopia and presbyopia treatment market in the U.S. is accelerated by the systemic reforms of Medicaid and Medicare. Medicare has spent USD 800.8 million in 2024 on the myopia and presbyopia treatment, which is a rise of 15.6% since 2020. Further, the CDC and NIH together have backed research programs regarding innovations in presbyopia pharmacological therapies, supporting start-ups to enter the market. Medicaid extended coverage to an extra 10.5% of enrollees in 2024 by allocating USD 1.6 billion for vision-related treatment. The U.S. market is positioned as the global growth engine due to the advantages of new therapies and regulatory policies under the FDA for vision-related treatments.

Asia Pacific Market Insights

The APAC presbyopia and myopia treatment market is set to grow strongly by holding the market share of 23.1% at CAGR 7.9% by 2037. The APAC market is fueled by increasing patient numbers, an ageing population, and continued government investment in the healthcare sector. Japan and South Korea are experiencing rising report of presbyopia, while India and China are struggling with alarming increases in myopia in younger age groups. Technological advancements in laser treatments, drug development, and tele-ophthalmology platforms are revolutionizing patient accessibility and treatment administration. Local API manufacturing in the region is also driving treatments to become more economical. These factors, along with significant R&D spending in Japan and South Korea, are expected to drive growth throughout the APAC market.

China holds the largest share in the myopia and presbyopia treatment market in the APAC region and is expected to have a revenue share of 29.2% by 2037. For the past five years, China government has been spending more on vision-related treatments with an increase of 15.7%, affecting the public health priority on vision-related problems. Further, in 2023, nearly 1.7 million people have undergone the myopia and presbyopia treatment due to the rise in screen time and aging population. Increasing access to pharmaceutical and surgical treatments in both urban and rural healthcare institutions, the National Medical Products Administration (NMPA) has expedited approvals for vision correction procedures.

Government Programs Initiated in the APAC Region

Europe Market Insights

The Europe myopia and presbyopia treatment market is growing and is expected to have a market share of 28.6% by 2037, with the region's aging population, greater exposure to screens, and government healthcare policies. The rising incidence of uncorrected refractive errors among the elderly and youth populations has led to the prioritization of vision correction therapy. Further, supportive EU rules have increased the availability of non-invasive procedures such as pharmacologic eye drops, and the popularity of LASIK and intraocular lens (IOL) operations has driven market growth. EU-wide backing, through the European Health Data Space, has made available €2.8 billion of funding for vision-related R&D from 2023 to 2027. Patterns of digital eye strain and myopia development in children have set in motion early intervention programs in Germany, France, and the UK.

Germany leads the myopia and presbyopia treatment market in Europe and is projected to hold the market share of 26.9% by 2037. The market leads with the government spending, and in 2024 government has reached €4.5 billion for vision treatments. As per the Federal Ministry of Health, the demand for vision-related treatments has grown by 12.6% since 2021 and is fueled by high uptake of intraocular lenses and refractive surgeries, and an aging population. The extensive compensation provided by Germany's statutory health insurance system for advanced remedial treatments encourages robust market activity from both domestic and international firms.